Phathom Pharmaceuticals Inc
NASDAQ:PHAT
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.21
19.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PHAT stock under the Base Case scenario is 12.09 USD. Compared to the current market price of 9.28 USD, Phathom Pharmaceuticals Inc is Undervalued by 23%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Phathom Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PHAT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Phathom Pharmaceuticals Inc
Balance Sheet Decomposition
Phathom Pharmaceuticals Inc
Current Assets | 373.8m |
Cash & Short-Term Investments | 334.7m |
Receivables | 21.1m |
Other Current Assets | 18.1m |
Non-Current Assets | 13.2m |
PP&E | 2.5m |
Other Non-Current Assets | 10.7m |
Current Liabilities | 65.3m |
Accounts Payable | 7.1m |
Accrued Liabilities | 38m |
Other Current Liabilities | 20.2m |
Non-Current Liabilities | 508.9m |
Long-Term Debt | 498.1m |
Other Non-Current Liabilities | 10.8m |
Earnings Waterfall
Phathom Pharmaceuticals Inc
Revenue
|
26.3m
USD
|
Cost of Revenue
|
-4.3m
USD
|
Gross Profit
|
21.9m
USD
|
Operating Expenses
|
-309.9m
USD
|
Operating Income
|
-287.9m
USD
|
Other Expenses
|
-51.5m
USD
|
Net Income
|
-339.4m
USD
|
Free Cash Flow Analysis
Phathom Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
PHAT Profitability Score
Profitability Due Diligence
Phathom Pharmaceuticals Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Phathom Pharmaceuticals Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
PHAT Solvency Score
Solvency Due Diligence
Phathom Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Phathom Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PHAT Price Targets Summary
Phathom Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for PHAT is 23.02 USD with a low forecast of 12.12 USD and a high forecast of 29.4 USD.
Dividends
Current shareholder yield for PHAT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Contact
IPO
Employees
Officers
The intrinsic value of one PHAT stock under the Base Case scenario is 12.09 USD.
Compared to the current market price of 9.28 USD, Phathom Pharmaceuticals Inc is Undervalued by 23%.